


## JAK3-IN-11

## Chemical Properties

CAS No. :	2412734-00-8
Formula:	C <sub>23</sub> H <sub>23</sub> N <sub>5</sub> O <sub>2</sub>
Molecular Weight:	401.46
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	JAK3-IN-11 (Compound 12) exhibits potent, noncytotoxic, irreversible, orally active JAK3 inhibitory activity (IC <sub>50</sub> = 1.7 nM) with an excellent selectivity profile (>588-fold compared to other JAK isoforms), covalently binds to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T-cell proliferation which is a promising tool for studying autoimmune diseases [1].
Targets(IC <sub>50</sub> )	Others,JAK
In vitro	JAK3-IN-11 (Compound 12) exhibits strong immunosuppressive activity by selectively inhibiting JAK3, without significant cytotoxic effects at 10 μM over 72 hours. It suppresses T cell proliferation with IC <sub>50</sub> values of 0.83 μM and 0.77 μM under anti-CD3/CD28 and IL-2 stimulation, respectively, and inhibits IL-2 or IL-15-induced STAT5 phosphorylation within 1 hour in a dose-dependent manner (0-10 μM). The compound covalently and irreversibly binds to JAK3, with effectiveness confirmed by cell proliferation assays using mouse T cells and Western blot analysis for phosphorylation status, indicating modulation of relevant immune pathways.
In vivo	JAK3-IN-11 (Compound 12) effectively inhibits oxazolone (OXZ)-induced delayed-type hypersensitivity (DTH) in Balb/c mice in a dose-dependent manner when administered orally at doses of 0-30 mg/kg over a 6-day challenge phase, with 3, 10, and 30 mg/kg doses reducing DTH responses. In male ICR mice, preliminary pharmacokinetic analysis following oral gavage and intravenous administration at 30 mg/kg and 10 mg/kg, respectively, measured parameters such as AUC(0-t), AUC(0-∞), MRT, Vz, CLz, t <sub>1/2</sub> , C <sub>max</sub> , and bioavailability, providing insights into the compound's pharmacokinetics.

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.4909 mL	12.4545 mL	24.9091 mL
5 mM	0.4982 mL	2.4909 mL	4.9818 mL
10 mM	0.2491 mL	1.2455 mL	2.4909 mL
50 mM	0.0498 mL	0.2491 mL	0.4982 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481